ENLV, IL0011319527

Enlivex announces 1-for-16 reverse split for Enlivex stock

Published on 10/25/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Split starts October 27, 2026, combining 16 shares into one. The change cuts Enlivex stock's issued shares from 24,511,905 to 1,531,995.

Reverse split and trial timing

Enlivex announced a 1-for-16 reverse split on October 22, 2026.
The company expects six-month Phase 2b data by mid-2027 after reducing its workforce by 60 percent.
Split-adjusted trading is scheduled to begin on October 27, 2026.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex (ISIN IL0011319527) announced a 1-for-16 reverse share split on October 22, 2026, with split-adjusted trading scheduled to begin on October 27. According to GlobeNewswire, every 16 ordinary shares will become one, while issued and outstanding shares are set to fall from 24,511,905 to 1,531,995.

Share count changes on October 27

The reverse split is designed to lift the per-share trading level without changing an investor's ownership percentage, apart from adjustments caused by rounding fractional shares. Enlivex said its authorized share count will decline from 158,333,333 to 9,895,833, while par value will rise from NIS 6.00 to NIS 96.00. Warrants and options will receive proportionate adjustments, according to GlobeNewswire.

What does the trial plan change?

Enlivex's October 19 cost reduction plan concentrates spending on the Phase 2b trial of Allocetra for age-related primary knee osteoarthritis. The company said it would wind down unrelated non-clinical research and reduce its workforce by 60 percent, while management salaries would fall by 20 percent and the chief executive's salary by 40 percent. GlobeNewswire reported that topline six-month data are expected by mid-2027.

Dates investors can track

The next dated corporate event is October 27, 2026, when split-adjusted trading is scheduled to start on Nasdaq. The next clinical milestone is the expected mid-2027 six-month Phase 2b readout, with the timing stated in the October 19 release by GlobeNewswire.

Stock context after October 23

On Nasdaq, Enlivex last stood at USD 0.17 on October 23, 2026 at 4:00 p.m. ET. Its market capitalization was USD 2.9 million and its 52-week range was USD 0.17 to USD 27.15 as of that date. The split therefore addresses the share-count structure and Nasdaq listing mechanics, while the clinical program remains the company's principal operating milestone.

The further course of trading is shown by the continuously updated real-time quote of Enlivex stock.